Latest Breaking News On - Novartis oncology communications - Page 1 : comparemela.com

Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer

Novartis Kisqali® adds one more year of survival benefit for broadest set of patients, including those with aggressive HR+/HER2- advanced breast cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalNew jerseySan antonioEast hanoverComunidad autonoma de catalunaIsabella zinckJeff legosNicole zinsli sommFloriana riccio furnariSamir shahParag mahantiJulie masowSloan simpsonDenisea yardleyAlina levchuk

Novartis Pharma AG: Novartis presents new data in breast and prostate cancer at ESMO

Overall survival results from pooled exploratory analysis of MONALEESA trials in patients with aggressive HR+/HER2- advanced breast cancer treated with Kisqali Data from VISION study reporting associations

United statesIsabella zinckJeff legosNicole zinsli sommSamir shahJulie masowParag mahantiSloan simpsonAlina levchukNovartis institutes for biomedical researchAstex pharmaceuticalsNovartis oncology communicationsNovartis us external communicationsNovartis external communicationsExchange commissionGlobal head of oncology hematology development

Novartis Pharma AG: Novartis receives positive CHMP opinion for Scemblix, a novel treatment for adult patients with chronic myeloid leukemia

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least

United statesEast hanoverIsabella zinckHaseeb ahmadAmy wolfNicole zinsli sommFloriana riccio furnariSamir shahParag mahantiJulie masowSloan simpsonAndreas hochhausAlina levchukOncology at jena university hospitalAmerican society for clinical oncologyEuropean hematology association

Investegate |NOVARTIS AG CHF0 50(REGD) Announcements | NOVARTIS AG CHF0 50(REGD): Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

United statesIsabella zinckVivek subbiahDan connellyNovartis tafinlarNicole zinsli sommSamir shahParag mahantiJulie masowSloan simpsonAlina levchukReshema kemps polancoDivision of cancer medicineUniversity of texas md anderson cancer centerDrug administrationNovartis oncology communications

Novartis Pharma AG: Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

Tafinlar + Mekinist, the worldwide targeted therapy leader in BRAF/MEK-inhibition, is the first and only therapy to be approved with a tumor-agnostic indication for adult and pediatric patients with solid

United statesIsabella zinckVivek subbiahDan connellyNicole zinsli sommSamir shahJulie masowParag mahantiSloan simpsonAlina levchukReshema kemps polancoDivision of cancer medicineUniversity of texas md anderson cancer centerDrug administrationNovartis oncology communicationsNovartis us external communications